The upcoming earnings report will provide insights into Renalytix's financial performance. While the estimated EPS is negative, the company's past performance has shown mixed results, with share price changes following earnings releases. Given the 48.51% decline in share price over the last 52 weeks, long-term shareholders may be unhappy. However, the short-term impact on the stock price will depend on the actual EPS and any guidance provided by the company.